Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24894599 | 1.00 | SLC6A2 (0.58) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL27303564 | 1.00 | SLC6A2 (0.58) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL30039527 | 1.00 | SLC6A2 (0.58) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL22710225 | 1.00 | SLC6A2 (0.58) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL20193189 | 1.00 | SLC6A2 (0.58) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL8717719 | 0.92 | SLC6A2 (0.54) | SLC6A2PDE4DBCHEACHECYP2C19 | |
| SCHEMBL20843083 | 0.89 | SLC6A2 (0.53) | SLC6A2PDE4DBCHEACHETSHR | |
| SCHEMBL19145004 | 0.89 | SLC6A2 (0.69) | SLC6A2PDE4DBCHEACHEPDPK1 | |
| SCHEMBL9008118 | 0.87 | SLC6A2 (0.50) | SLC6A2PDE4DBCHEACHETSHR | |
| SCHEMBL17012295 | 0.87 | SLC6A2 (0.47) | SLC6A2PDE4DBCHEACHEPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | REYOUNG CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023011597-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2023-02-09 | — | — | WO | disclosed |
| EP-3315502-A1 | C,O-SPIRO ARYL GLYCOSIDE COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | TLR9, XIAP, ENPP2 | SLC6A2 3027/4885PDE4D 1753/4885BCHE 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.